{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:36:05Z","timestamp":1767591365680,"version":"3.48.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To construct a management and prevention program for targeted therapy-induced hand-foot skin reactions (HFSR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A systematic review with meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on a literature review and expert consensus meetings, a two-round expert panel discussion involving 10 experts was conducted to finalize the HFSR management and prevention program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Articles were systematically searched on the CNKI, Wanfang Database, VIP, PubMed, UpToDate, Embase, and Cochrane Library, and guideline publication websites, NGC, NCCN, NICE, SIGN and ESMO databases from inception up to June 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final program comprised 8 primary indicators, 16 secondary indicators, 36 tertiary indicators, and 54 quaternary entries. These include baseline level and hand-foot skin assessment, skin erythema care, skin keratosis care, skin blister management, skin ulcer care, skin pain management, management of other accompanying symptoms, and hand-foot protection and prevention education.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This management and prevention program, constructed based on evidence and expert discussion, is scientifically sound and clinically applicable, providing reliable guidance for the management and prevention of HFSR in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>Based on the best available evidence for managing and preventing hand-foot skin reactions induced by targeted therapies, we recommend that nursing leaders implement personalized symptom management plans tailored to the common symptoms of these reactions. Such an approach may help in the early detection of hand-foot skin reactions and alleviate patients\u2019 skin pain effectively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1718588","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:32:06Z","timestamp":1767591126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of a management and prevention program for targeted therapy-induced hand-foot skin reaction"],"prefix":"10.3389","volume":"12","author":[{"given":"Xi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubao","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors Sorafenib and Sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/theoncologist.2014-0219","article-title":"The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology","volume":"20","author":"Anderson","year":"2015","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and Management of Hand-Foot Skin Reaction Associated with Sorafenib in combination with cytotoxic chemotherapy: experience in breast Cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.13267\/j.cnki.syzlzz.2016.05.019","article-title":"Advances in the diagnosis and treatment of hand-foot syndrome induced by antitumor drugs","volume":"31","author":"Li","year":"2016","journal-title":"Practical Oncol J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1186\/s12913-022-08610-1","article-title":"The effectiveness of case management for cancer patients: an umbrella review","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.suponc.2010.12.007","article-title":"Management of Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse","volume":"9","author":"Manchen","year":"2011","journal-title":"J Support Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0174831","DOI":"10.1371\/journal.pone.0174831","article-title":"Guideline appraisal with AGREE II: systematic review of the current evidence on how users handle the 2 overall assessments","volume":"12","author":"Hoffmann-E\u00dfer","year":"2017","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e41779","DOI":"10.1097\/MD.0000000000041779","article-title":"Efficacy and safety of Shenfu injection on bradyarrhythmia: a systematic review and meta-analysis","volume":"104","author":"Wei","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.16821\/j.cnki.hsjx.2018.08.008","article-title":"Methodological quality assessment of systematic reviews: JBI methodology for systematic reviews of different study types","volume":"33","author":"Gu","year":"2018","journal-title":"J Nurs Contin Educ"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and Management of Dermatological Toxicities Related to anticancer agents: ESMO clinical practice guidelines\u2606","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1188\/20.ONF.539-556","article-title":"ONS guidelines\u2122 for cancer treatment-related skin toxicity","volume":"47","author":"Williams","year":"2020","journal-title":"Oncol Nurs Forum"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.16821\/j.cnki.hsjx.2019.22.001","article-title":"Chinese cancer symptom management practice guidelines: skin reactions","volume":"34","author":"Zhang","year":"2019","journal-title":"J Nurs Contin Educ"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"E149","DOI":"10.1188\/20.ONF.E149-E160","article-title":"Targeted therapy- and chemotherapy-associated skin toxicities: systematic review and meta-analysis","volume":"47","author":"Ding","year":"2020","journal-title":"Oncol Nurs Forum"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1007\/s00520-022-07175-3","article-title":"Prophylactic strategies for hand-foot syndrome\/skin reaction associated with systemic Cancer treatment: a Meta-analysis of randomized controlled trials","volume":"30","author":"Pandy","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.critrevonc.2011.08.005","article-title":"Early detection, prevention and Management of Cutaneous Adverse Events due to Sorafenib: recommendations from the Sorafenib working group","volume":"82","author":"Bracarda","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of Dermatologic Adverse Events from Cancer therapies: recommendations of an expert panel","volume":"95","author":"Cury-Martins","year":"2020","journal-title":"An Bras Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s12094-018-1953-x","article-title":"Clinical Management of Cutaneous Adverse Events in patients on targeted anticancer therapies and immunotherapies: a National Consensus Statement by the Spanish academy of dermatology and venereology and the Spanish Society of Medical Oncology","volume":"21","author":"Gr\u00e1valos","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.19872\/j.cnki.2095-7815.2020.02.002","article-title":"Expert consensus on targeted therapy for liver cancer (draft)","volume":"7","author":"Han","year":"2020","journal-title":"Hepatocellular Carcinoma Electronic J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1548-5315(11)70385-0","article-title":"Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors","volume":"7","author":"Wood","year":"2010","journal-title":"Commun Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3969\/j.issn.1007-3639.2015.08.001","article-title":"Expert consensus on adverse reaction management of targeted therapy for advanced renal cell carcinoma in China (2015 edition)","volume":"25","author":"Ye","year":"2015","journal-title":"Chin J Cancer"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.09.012","article-title":"Effect of urea cream on Sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: a multicenter, randomised, double-blind controlled study","volume":"140","author":"Lee","year":"2020","journal-title":"Eur J Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e18849","DOI":"10.1097\/MD.0000000000018849","article-title":"Clinical study for external Chinese herbal medicine LC09 treating hand-foot skin reaction associated with the antitumor targeted drugs: protocol for a prospective, randomized, controlled, double-blind, and monocentric clinical trial","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e038276","DOI":"10.1136\/bmjopen-2020-038276","article-title":"Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study","volume":"10","author":"Zenda","year":"2020","journal-title":"BMJ Open"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.12010\/j.issn.1673-5846.2022.09.010","article-title":"Current implementation status and improvement suggestions for China's anti-tumor targeted drug insurance policy","volume":"17","author":"Liu","year":"2022","journal-title":"Chinese J Pharmaceutical Econ"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41401-021-00679-4","article-title":"Role of TRPM2 in brain tumours and potential as a drug target","volume":"43","author":"Ji","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/IJN.S466042","article-title":"Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.7150\/ijbs.78535","article-title":"The emerging role of super-enhancers as therapeutic targets in the digestive system tumors","volume":"19","author":"Li","year":"2023","journal-title":"Int J Biol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.20251\/j.cnki.1003-3734.2018.22.020","article-title":"A systematic review of literature on hand-foot skin reactions induced by Apatinib","volume":"27","author":"Li","year":"2018","journal-title":"Chinese J New Drugs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3870\/j.issn.1001-4152.2016.02.084","article-title":"Application of knowledge translation model in evidence-based practice","volume":"31","author":"Zhou","year":"2016","journal-title":"J Nurs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejon.2018.12.001","article-title":"Unmet needs of Cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: a qualitative study","volume":"38","author":"Komatsu","year":"2019","journal-title":"Eur J Oncol Nurs"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"Oncologist"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1718588\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:32:12Z","timestamp":1767591132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1718588\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":31,"alternative-id":["10.3389\/fmed.2025.1718588"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1718588","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1718588"}}